Verona Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Verona Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Verona Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Verona Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Verona Pharma Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Verona Pharma Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 29 Jul 2022 | Lorem |
| Verona Pharma to submit Phase IIb RPL554 COPD data for ERS meeting in September, CEO says | 29 May 2018 | Manasi Vaidya |
| Verona plans RPL554 Phase II trial on top of double and triple therapies in COPD, CEO says | 27 Mar 2018 | Manasi Vaidya |
| Verona’s Phase IIb maintenance COPD study with RPL554 elicits efficacy optimism; experts eye toxicity data | 28 Sep 2017 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer